- Home
- MTDR vs JAZZ Comparison
MTDR vs JAZZ Comparison
Compare MTDR & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTDR
- JAZZ
- Stock Information
- Founded
- MTDR 2003
- JAZZ 2003
- Country
- MTDR United States
- JAZZ Ireland
- Employees
- MTDR N/A
- JAZZ N/A
- Industry
- MTDR Oil & Gas Production
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- MTDR Energy
- JAZZ Health Care
- Exchange
- MTDR Nasdaq
- JAZZ Nasdaq
- Market Cap
- MTDR 7.1B
- JAZZ 6.5B
- IPO Year
- MTDR 2012
- JAZZ 2007
- Fundamental
- Price
- MTDR $53.11
- JAZZ $122.97
- Analyst Decision
- MTDR Strong Buy
- JAZZ Buy
- Analyst Count
- MTDR 14
- JAZZ 14
- Target Price
- MTDR $74.69
- JAZZ $173.93
- AVG Volume (30 Days)
- MTDR 1.1M
- JAZZ 646.0K
- Earning Date
- MTDR 02-18-2025
- JAZZ 11-06-2024
- Dividend Yield
- MTDR 1.88%
- JAZZ N/A
- EPS Growth
- MTDR 7.36
- JAZZ 458.10
- EPS
- MTDR 7.55
- JAZZ 7.04
- Revenue
- MTDR $3,099,645,000.00
- JAZZ $3,992,712,000.00
- Revenue This Year
- MTDR $34.10
- JAZZ $7.51
- Revenue Next Year
- MTDR $19.49
- JAZZ $6.82
- P/E Ratio
- MTDR $7.03
- JAZZ $17.48
- Revenue Growth
- MTDR 23.82
- JAZZ 5.23
- 52 Week Low
- MTDR $47.15
- JAZZ $99.06
- 52 Week High
- MTDR $71.08
- JAZZ $134.17
- Technical
- Relative Strength Index (RSI)
- MTDR 35.13
- JAZZ 54.14
- Support Level
- MTDR $55.86
- JAZZ $119.14
- Resistance Level
- MTDR $56.14
- JAZZ $125.77
- Average True Range (ATR)
- MTDR 1.74
- JAZZ 3.19
- MACD
- MTDR -0.71
- JAZZ -0.27
- Stochastic Oscillator
- MTDR 1.15
- JAZZ 55.59
About MTDR Matador Resources Company
Matador Resources Co is an independent energy company engaged in the exploration, development, production, and acquisition of oil and natural gas resources. The majority of the company's assets are located in the United States, with an emphasis on oil and natural gas shale and other unconventional plays. Along with maintaining a portfolio of oil and natural gas properties, Matador works to identify and develop midstream opportunities that support and enhance its exploration and development business.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.